Note 13 - Income Taxes - Deferred Tax Assets and Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Depreciation		$ 100
Research & Experimental and Orphan Drug tax credit carry-forwards	35,435	33,496
NYS investment tax credit carry-forwards	1,282	1,284
Net operation loss carry-forwards	188,588	177,313
Capitalized research and development expenditures	1,066	3,066
Stock compensation	5,236	5,666
Other items	819	1,279
Total gross deferred tax assets	232,426	222,204
Less valuation allowance	(232,174)	(217,382)
Deferred tax assets	252	4,822
Indefinite-lived intangibles	(136)	(6,397)
Depreciation and amortization	(144)
Deferred tax liabilities	(280)	(6,397)
Net deferred tax liability	$ (28)	$ (1,575)